# BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) Highlights Board Appointments and AVERSA Fentanyl Milestones From Annual Meeting

Nutriband (NASDAQ: NTRB) (NASDAQ: NTRBW) provided shareholders with an update following its 2026 Annual Shareholders Meeting held Jan. 24, 2026, in Orlando, Florida, highlighting the appointment of two new directors, Alessandro Puddu and Viorica Carlig, and outlining key progress in the development of AVERSA(TM) FENTANYL. During 2025, the company strengthened its exclusive partnership with Kindeva, completed commercial manufacturing scale-up, expanded global patent protection including new U.S. and Macao patents, engaged with the U.S. Food and Drug Administration through a Type C meeting, and advanced branding initiatives for AVERSA(TM) FENTANYL. Looking ahead to 2026, Nutriband plans to advance toward an NDA filing by extending patent protection potentially to 2046, manufacturing clinical supplies, filing an Investigational New Drug application, and initiating a Human Abuse Liability clinical study.

 To view the full press release, visit https://ibn.fm/cp5lC

 About Nutriband Inc.

 We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

 NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/biomednewsbreaks-nutriband-inc-nasdaq-ntrb-nasdaq-ntrbw-highlights-board-appointments-and-aversa-fentanyl-milestones-from-annual-meeting/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/nutriband-advances-abuse-deterrent-fentanyl-patch-toward-fda-filing/c7449abd83336e63c94a9e21bfda0232) 

 

 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/261/30/pendXnzn.webp)